Application of reagent for detecting MEOX1 in preparation of product for diagnosing Alport syndrome related diseases

By detecting the expression level of MEOX1, performing PCR detection using the primers and antibodies in the kit, and combining single-cell transcriptomics and immunohistochemistry analysis, the diagnostic difficulties of Alport syndrome-related diseases were solved, new therapeutic targets were provided, and the effectiveness of diagnosis and treatment was improved.

CN120758620APending Publication Date: 2025-10-10WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511108031.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-08
Publication Date
2025-10-10

AI Technical Summary

Technical Problem

Existing technologies make it difficult to effectively diagnose and treat Alport syndrome-related diseases, especially diffuse esophageal leiomyomatosis, due to the lack of a clear pathogenesis and effective detection methods.

Method used

MEOX1 is used as a target, and the expression level of MEOX1 is detected. PCR detection is performed using the primers and antibodies in the kit. Combined with single-cell transcriptomics and immunohistochemistry analysis, the expression of MEOX1 in Alport syndrome-related diseases is determined, and diagnosis and treatment plans are provided.

Benefits of technology

It has achieved accurate diagnosis of Alport syndrome-related diseases, revealed the disease's multi-organ involvement pathogenic mechanism, provided new targets for treatment, and improved the effectiveness of diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of a reagent for detecting MEOX1 in preparation of a product for diagnosing Alport syndrome related diseases, and relates to the technical field of tumors. According to the research of the inventor, the deletion of COL4A5 / COL4A6 gene fragments causes high expression of MEOX1 on basement membranes of multiple organ tissues of AS, so that the expression level of MEOX1 can be used for AS detection. In addition, the inventor researches and confirms that the bases of the kidney biopsy tissue and the esophageal lesion tissue of the AS-DL patient involve a common pathogenic mechanism of multiple visceral smooth muscles for AS-DL, which provides an important research clue for researching the common pathogenic mechanism of AS leiomyomatosis.
Need to check novelty before this filing date? Find Prior Art